[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Allergy Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100624696",false,"NCT07412990","GRASS (Grass MATA MPL Real-world Assessment Study)","Eine Prospektive, Offene, Multizentrische, Nicht-interventionelle Studie Zur Erhebung Von Daten Zur Anwendung Von Grass MATA MPL 27 600 SU Und Compliance in Der täglichen Klinischen Praxis Bei Erwachsenen Gräserpollen- Allergikern","GRASS","At the physician's discretion and based on the current Summary of Product Characteristics (SmPC), study participation may be offered to patients who\n\n* are male and female patients\n* are 18 years of age or older\n* treated in accordance with the SmPC of Grassmuno® for IgE-mediated moderate to severe allergic rhinitis and\u002For rhinoconjunctivitis (without asthma or with well-controlled asthma) triggered by grass pollen.\n* Patients will only be enrolled in the study after the treatment decision has been made\n\nExclusion Criteria:\n\nAt the physician's discretion, the study should not be offered to the following patients:\n\n* Patients who are not sufficiently proficient in or do not adequately understand the German language, as this would prevent adequate comprehension of study-relevant documents.\n* In addition, patients should not be included if any of the contraindications listed in the current Summary of Product Characteristics (SmPC) are present.","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","Objective of this non-interventional study (NIS) is to collect data on the use of Grassmuno® in routine clinical practice.",[24],"Grass Pollen Allergy",[26],"Allergy, Grass-pollen, AIT, SCIT","RECRUITING","2026-03-19",{"date":30,"type":31},"2026-03-20","ACTUAL",{"date":33,"type":31},"2026-03-11",{"date":35,"type":20},"2028-10-02",{"name":37,"class":38},"Allergy Therapeutics","INDUSTRY",""]